Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) announced that the first three participants have received their initial dose of intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN clinical trial. This trial aims to evaluate the efficacy of intranasal foralumab in individuals with amyotrophic lateral sclerosis (ALS) and is co-funded by the ALS Association. The study will take place at multiple locations, including the Healey & AMG Center in Boston and other sites in Chicago, Minneapolis, and Davie.